BMS-470539

BMS-470539
Clinical data
Routes of
administration
S.C.
ATC code
  • None
Legal status
Legal status
  • In general: non-regulated
Pharmacokinetic data
Bioavailability100% (with S.C. administration)
Elimination half-life1.7 hours
Identifiers
  • (2S)-2-amino-N-[(1R)-2-(4-butanoyl-4-phenyl-1-piperidyl)-1-[(4-methoxyphenyl)methyl]-2-oxo-ethyl]-3-(3-methylimidazol-4-yl)propanamide dihydrochloride
CAS Number
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC32H41N5O4
Molar mass559.711 g·mol−1
3D model (JSmol)
  • CCCC(=O)C1(CCN(CC1)C(=O)[C@@H](Cc2ccc(cc2)OC)NC(=O)[C@H](Cc3cncn3C)N)c4ccccc4
  • InChI=1S/C32H41N5O4.2ClH/c1-4-8-29(38)32(24-9-6-5-7-10-24)15-17-37(18-16-32)31(40)28(19-23-11-13-26(41-3)14-12-23)35-30(39)27(33)20-25-21-34-22-36(25)2;;/h5-7,9-14,21-22,27-28H,4,8,15-20,33H2,1-3H3,(H,35,39);2*1H/t27-,28+;;/m0../s1 checkY
  • Key:DUAOBJHRUKFKIH-YDVFRNEYSA-N checkY
 X markNcheckY (what is this?)  (verify)

BMS-470539 is a small-molecule experimental drug which acts as a potent and highly selective full agonist of the MC1 receptor. It was discovered in 2003 as part of an effort to understand the role of the MC1 receptor in immunomodulation, and has since been used in scientific research to determine its role in inflammatory processes. The compound was designed with the intention of mimicking the central His-Phe-Arg-Trp pharmacophore of the melanocortins, and this proved to be successful based on its favorable pharmacodynamic profile.

See also